Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit

Dow Jones04-29

By Amanda Lee

Sinopharm Group's shares fell by their most in more than six months in early trade after the Chinese state-owned pharmaceutical giant's quarterly profit fell amid higher operating costs and impairments.

Shares were down 6.4% at 20.45 Hong Kong dollars ($2.61) early Monday, taking them into the red for the year.

Sinopharm said ahead of trading that first-quarter profit dropped 11% from a year earlier to 1.42 billion yuan ($196 million). A 1.2% rise in total operating revenue was offset by a 1.5% rise in total operating cost, while credit impairment losses expanded 15% on year.

The company separately said its board had approved a plan to raise CNY30.0 billion via the issuance of corporate debt to repay loans and matured debt, replenish working capital and fund project construction, saying the moves would help trim financing costs and improve debt structure.

The issuance, which is subject to approval by shareholders and regulators, will comprise CNY25.0 billion in short-term debt with a one-year term and CNY5.0 billion in debt with a term of up to 10 years.

Write to Amanda Lee at amanda.lee@wsj.com

(END) Dow Jones Newswires

April 28, 2024 23:31 ET (03:31 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431217660?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-29 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2431217660","market":"sg","top_or_hot":-1,"title":"Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Amanda Lee \n</p>\n<pre>\n \n</pre>\n<p>\n  Sinopharm Group's shares fell by their most in more than six months in early trade after the Chinese state-owned pharmaceutical giant's quarterly profit fell amid higher operating costs and impairments. \n</p>\n<p>\n  Shares were down 6.4% at 20.45 Hong Kong dollars ($2.61) early Monday, taking them into the red for the year. \n</p>\n<p>\n  Sinopharm said ahead of trading that first-quarter profit dropped 11% from a year earlier to 1.42 billion yuan ($196 million). A 1.2% rise in total operating revenue was offset by a 1.5% rise in total operating cost, while credit impairment losses expanded 15% on year. \n</p>\n<p>\n  The company separately said its board had approved a plan to raise CNY30.0 billion via the issuance of corporate debt to repay loans and matured debt, replenish working capital and fund project construction, saying the moves would help trim financing costs and improve debt structure. \n</p>\n<p>\n  The issuance, which is subject to approval by shareholders and regulators, will comprise CNY25.0 billion in short-term debt with a one-year term and CNY5.0 billion in debt with a term of up to 10 years. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Amanda Lee at amanda.lee@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 28, 2024 23:31 ET (03:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-29 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Amanda Lee \n\n\n \n\n\n  Sinopharm Group's shares fell by their most in more than six months in early trade after the Chinese state-owned pharmaceutical giant's quarterly profit fell amid higher ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1500","symbol_name":"做空集合股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2431217660","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431217660","pubTimestamp":1714361460,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sinopharm Group's shares fell by their most in more than six months in early trade after the Chinese state-owned pharmaceutical giant's quarterly profit fell amid higher operating costs and impairments.Shares were down 6.4% at 20.45 Hong Kong dollars  early Monday, taking them into the red for the year.Sinopharm said ahead of trading that first-quarter profit dropped 11% from a year earlier to 1.42 billion yuan . A 1.2% rise in total operating revenue was offset by a 1.5% rise in total operating cost, while credit impairment losses expanded 15% on year.The company separately said its board had approved a plan to raise CNY30.0 billion via the issuance of corporate debt to repay loans and matured debt, replenish working capital and fund project construction, saying the moves would help trim financing costs and improve debt structure.The issuance, which is subject to approval by shareholders and regulators, will comprise CNY25.0 billion in short-term debt with a one-year term and CNY5.0 b","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1500":"做空集合股","01099":"国药控股","BK1197":"保健护理产品经销商","SHTDY":"国药控股ADR","BK4175":"保健护理产品经销商","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK1515":"抗疫概念"},"translate_title":"国药集团股价下跌，成本上升削减季度利润","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1,"SHTDY":0.9},"content_text":"By Amanda Lee \n\n\n \n\n\n  Sinopharm Group's shares fell by their most in more than six months in early trade after the Chinese state-owned pharmaceutical giant's quarterly profit fell amid higher operating costs and impairments. \n\n\n  Shares were down 6.4% at 20.45 Hong Kong dollars ($2.61) early Monday, taking them into the red for the year. \n\n\n  Sinopharm said ahead of trading that first-quarter profit dropped 11% from a year earlier to 1.42 billion yuan ($196 million). A 1.2% rise in total operating revenue was offset by a 1.5% rise in total operating cost, while credit impairment losses expanded 15% on year. \n\n\n  The company separately said its board had approved a plan to raise CNY30.0 billion via the issuance of corporate debt to repay loans and matured debt, replenish working capital and fund project construction, saying the moves would help trim financing costs and improve debt structure. \n\n\n  The issuance, which is subject to approval by shareholders and regulators, will comprise CNY25.0 billion in short-term debt with a one-year term and CNY5.0 billion in debt with a term of up to 10 years. \n\n\n \n\n\n  Write to Amanda Lee at amanda.lee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 28, 2024 23:31 ET (03:31 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431217660"}